Ruiz-Roso Guerra, María BelénEcheverry Alzate, VíctorRuiz-Roso Calvo De La Mora, BaltasarQuintela, JoséBallesteros Rodrigálvarez, Sandra MaríaLahera Julia, VicenteHeras Jiménez, Natalia De LasLópez Moreno, José AntonioMartín Fernández, Beatriz2023-06-172023-06-172018Ruiz-Roso Guerra, M. B., Echeverry Alzate, V., Ruiz-Roso Calvo De La Mora, B. et al. «Low Phytanic Acid-Concentrated DHA Prevents Cognitive Deficit and Regulates Alzheimer Disease Mediators in an ApoE−/− Mice Experimental Model». Nutrients, vol. 11, n.o 1, diciembre de 2018, p. 11. DOI.org (Crossref), https://doi.org/10.3390/nu11010011.2072-664310.3390/nu11010011https://hdl.handle.net/20.500.14352/19079Alzheimer’s disease (AD) is the main cause of dementia and cognitive impairment. It has been associated with a significant diminution of omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) levels in the brain. Clinical trials with DHA as a treatment in neurological diseases have shown inconsistent results. Previously, we reported that the presence of phytanic acid (PhA) in standard DHA compositions could be blunting DHA’s beneficial effects. Therefore, we aimed to analyze the effects of a low PhA-concentrated DHA and a standard PhA-concentrated DHA in Apolipoprotein E knockout (ApoEengAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/nu11010011https://www.mdpi.com/2072-6643/11/1/11open accessAlzheimer’sDHAApoE -/-Phytanic acidInflammationNeuroprotectionOxidationNeurociencias (Medicina)2490 Neurociencias